Sol-Gel Technologies Ltd.

Founded in 1997 and headquartered in Ness Ziona, Israel, Sol-Gel Technologies develops topical dermatological pharmaceuticals for treatment of severe skin conditions. The company's approved products include Twyneo, a once-daily topical cream for acne vulgaris, and Epsolay, a once-daily topical cream for papulopustular rosacea. Both products represent non-antibiotic treatment options in their respective indications.

The company's pipeline includes SGT-610, currently in Phase 3 clinical trials for Gorlin Syndrome, and SGT-210, which has completed Phase 1 testing for rare hyperkeratinization disorders including Darier disease, pityriasis versicolor, palmoplantar keratoderma, Olmsted syndrome, and related conditions. Sol-Gel operates through licensing agreements with Galderma Holding SA and Searchlight Pharma Inc., as well as a collaboration with Padagis Israel Pharmaceuticals Ltd.

The company operates with 34 full-time employees and maintains a geographic footprint across Israel, China, Switzerland, Canada, and other international markets. Sol-Gel is listed on Nasdaq and incorporated in Israel.